Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDK1 | Q15118 | 4/20 | 0.44 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.36 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | CA12 | O43570 | 2/20 | 0.35 |
| ▸ | CA1 | P00915 | 2/20 | 0.35 |
| ▸ | CA2 | P00918 | 2/20 | 0.35 |
| ▸ | CA9 | Q16790 | 2/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | DPP4 | P27487 | 1/20 | 0.32 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.31 |
| ▸ | GLA | P06280 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5560259 | 0.85 | PDK1 (0.59) | PDK1PDK2PDK3L3MBTL1CA12 | |
| SCHEMBL509358 | 0.85 | PDK1 (0.59) | PDK1PDK2PDK3L3MBTL1CA12 | |
| SCHEMBL15909553 | 0.85 | PDK1 (0.59) | PDK1PDK2PDK3L3MBTL1CA12 | |
| SCHEMBL17893278 | 0.80 | PDK1 (0.42) | PDK1PDK2PDK3L3MBTL1CA12 | |
| SCHEMBL19056488 | 0.80 | PDK1 (0.41) | PDK1PDK2PDK3L3MBTL1CA12 | |
| SCHEMBL570641 | 0.80 | PDK1 (0.41) | PDK1PDK2PDK3L3MBTL1CA12 | |
| SCHEMBL16797367 | 0.80 | PDK1 (0.41) | PDK1PDK2PDK3L3MBTL1CA12 | |
| SCHEMBL17791708 | 0.80 | PDK1 (0.41) | PDK1PDK2PDK3L3MBTL1CA12 | |
| SCHEMBL19056428 | 0.80 | PDK1 (0.41) | PDK1PDK2PDK3L3MBTL1CA12 | |
| Hydrochloric Acid SCHEMBL16058567 | 0.79 | PDK1 (0.40) | PDK1PDK2PDK3L3MBTL1CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022233302-A1 | PYRIMIDINONE DERIVATIVE AND PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION, AND USE | 上海赛默罗生物科技有限公司 | 2022-11-10 | — | — | WO | disclosed |
| EP-3856726-A1 | QUINAZOLINE DERIVATIVES AS TYROSINE KINASE INHIBITOR, COMPOSITIONS, METHODS OF MAKING THEM AND THEIR USE | Black Diamond Therapeutics, Inc. (US) | 2021-08-04 | — | — | EP | disclosed |
| WO-2020068867-A1 | QUINAZOLINE DERIVATIVES AS TYROSINE KINASE INHIBITOR, COMPOSITIONS, METHODS OF MAKING THEM AND THEIR USE | BLACK DIAMOND THERAPEUTICS, INC. (US) | 2020-04-02 | — | — | WO | disclosed |
| US-8541585-B2 | N-acyl cyclic amine derivative or pharmaceutically acceptable salt thereof | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2013-09-24 | — | — | US | disclosed |
| EP-2545046-A1 | N-ACYL CYCLIC AMINE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2013-01-16 | — | — | EP | disclosed |
| US-20120214790-A1 | N-ACYL CYCLIC AMINE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | DAINIPPON SUMITOMO PHARMA CO., LTD. | 2012-08-23 | — | — | US | disclosed |
| WO-2011111875-A1 | N-ACYL CYCLIC AMINE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2011-09-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120214790-A1 | N-ACYL CYCLIC AMINE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | GRIN2C, GRIN2A, GRIN2B | PDK1 4401/4885PDK2 3891/4885PDK3 3297/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.